Semaglutide and Cardiovascular Outcomes in Obesity | NEJM [eVZR5T3N4LY]
Semaglutide and Cardiovascular Outcomes in Obesity | NEJM [eVZR5T3N4LY]
| 1h 28m 28s | Video has closed captioning.
The GLP-1 receptor agonist semaglutide can reduce adverse cardiovascular events in patients with diabetes. Whether this effect extends to patients with overweight or obesity, but without diabetes, is unknown. New research findings are summarized in a short video. To see the full article, follow this link: #action diet pills #keto luxe acv gummies scam #health keto gummies review #free trial weight loss gummies
Aired: January 06, 2025
Buy Now:
Semaglutide and Cardiovascular Outcomes in Obesity | NEJM [eVZR5T3N4LY]
Fixed iFrame
Responsive iFrame
Problems Playing Video? | Closed Captioning
